GnRH antagonist protocols result in rapid suppression of pituitary activity and offer several advantages over GnRH agonist protocols, including a shorter duration of treatment, reduced risk of ovarian hyperstimulation syndrome (OHSS), lower gonadotropin requirements, and improved patient compliance (7). The gene discussed is GNRH1; the disease is ovarian hyperstimulation syndrome.